CRITICAL CARE - ADULTS / SPECIAL ARTICLE
Volatile anesthetics in the intensive care unit
1
Department of Anesthesia and Pain Medicine, Toronto General Hospital, Toronto, ON, Canada
Submission date: 2025-05-30
Acceptance date: 2025-06-15
Publication date: 2025-07-10
Corresponding author
Marcin Wąsowicz
Department of Anesthesia and Pain Medicine, Toronto General Hospital, Toronto, ON, Canada
Department of Anesthesia and Pain Medicine, Toronto General Hospital, Toronto, ON, Canada
Anaesthesiol Intensive Ther 2025;57(1):165-169
KEYWORDS
TOPICS
ABSTRACT
The use of volatile anesthetics as an alternative sedation modality in the intensive care
unit (ICU) has gained traction over the last several years. Volatile agents such as sevoflurane and isoflurane possess favorable pharmacokinetic and pharmacodynamic properties that make them suitable choices for titration of sedation in patients requiring
mechanical ventilation. Several studies have continued to demonstrate their efficacy
and safety particularly when assessing wake-up times and times to extubation in contrast to various intravenous sedatives. Leveraging the pharmacodynamic properties
of the volatile agents may also be beneficial in certain disease states. As there are devices currently available to enable delivery of volatile anesthetics to patients in the ICU,
ongoing studies exist to determine how to best use this sedation modality. This review
outlines the recent evidence and discusses perspectives on volatile-based sedation for
critically ill patients.
REFERENCES (41)
1.
Barr J, Fraser GL, Puntillo K, Ely EW, Gélinas C, Dasta JF, et al. Clinical practice guidelines for the management of pain, agitation, and delirium in adult patients in the intensive care unit. Crit Care Med 2013; 41: 263-306. DOI: 10.1097/CCM.0b013e3182783b72.
2.
Roberts RJ, Barletta JF, Fong JJ, Schumaker G, Kuper PJ, Papadopoulos S, et al. Incidence of propofol-related infusion syndrome in critically ill adults: a prospective, multicenter study. Crit Care 2009; 13: R169. DOI: 10.1186/cc8145.
3.
Keating GM. Dexmedetomidine: a review of its use for sedation in the intensive care setting. Drugs 2015; 75: 1119-1130. DOI: 10.1007/s40265-015-0419-5.
4.
Kim CS, McLaughlin KC, Romero N, Crowley KE. Evaluation of dexmedetomidine withdrawal and management after prolonged infusion. Clin Ther 2024; 46: 1034-1040. DOI: 10.1016/j.clinthera.2024.09.006.
5.
Devlin JW, Skrobik Y, Gélinas C, Needham DM, Slooter AJC, Pandharipande PP, et al. Clinical practice guidelines for the prevention and management of pain, agitation/sedation, delirium, immobility, and sleep disruption in adult patients in the ICU. Crit Care Med 2018; 46: e825-e873. DOI: 10.1097/CCM.0000000000003299.
6.
Jerath A, Parotto M, Wasowicz M, Ferguson ND. Volatile anesthetics. Is a new player emerging in critical care sedation? Am J Respir Crit Care Med 2016; 193: 1202-1212. DOI: 10.1164/rccm.201512-2435CP.
7.
Wąsowicz M, Jerath A. Expanding the use of volatile anesthetic agents beyond the operating room. Can J Anaesth 2014; 61: 905-908. DOI: 10.1007/s12630-014-0211-0.
8.
O’Gara B, Boncyk C, Meiser A, Jerath A, Bellgardt M, Jabaudon M, et al. Volatile anesthetic sedation for critically ill patients. Anesthesiology 2024; 141: 163-174. DOI: 10.1097/ALN.0000000000004994.
9.
Jerath A, Parotto M, Wasowicz M, Ferguson ND. Opportunity knocks? The expansion of volatile agent use in new clinical settings. J Cardiothorac Vasc Anesth 2018; 32: 1946-1954. DOI: 10.1053/j.jvca. 2017.12.035.
10.
Meiser A, Laubenthal H. Inhalational anaesthetics in the ICU: theory and practice of inhalational sedation in the ICU, economics, risk-benefit. Best Pract Res Clin Anaesthesiol 2005; 19: 523-538. DOI: 10.1016/j.bpa.2005.02.006.
11.
Campagna JA, Miller KW, Forman SA. Mechanisms of actions of inhaled anesthetics. N Engl J Med 2003; 348: 2110-2124. DOI: 10.1056/NEJMra021261.
12.
Preckel B, Bolten J. Pharmacology of modern volatile anaesthetics. Best Pract Res Clin Anaesthesiol 2005; 19: 331-348. DOI: 10.1016/ j.bpa.2005.01.003.
13.
Röhm KD, Mengistu A, Boldt J, Mayer J, Beck G, Piper SN. Renal integrity in sevoflurane sedation in the intensive care unit with the anesthetic-conserving device: a comparison with intravenous propofol sedation. Anesth Analg 2009; 108: 1848-1854. DOI: 10.1213/ane.0b013e3181a1988b.
14.
Taylor B, Scott TE, Shaw J, Chockalingam N. Renal safety of critical care sedation with sevoflurane: a systematic review and meta-analysis. J Anesth 2023; 37: 794-805. DOI: 10.1007/s00540-023-03227-y.
15.
Breheny FX, Kendall PA. Use of isoflurane for sedation in intensive care. Crit Care Med 1992; 20: 1062-1064. DOI: 10.1097/00003246-199207000-00027.
16.
Mondoñedo JR, McNeil JS, Amin SD, Herrmann J, Simon BA, Kacz-ka DW. Volatile anesthetics and the treatment of severe bronchospasm: a concept of targeted delivery. Drug Discov Today Dis Models 2015; 15: 43-50. DOI: 10.1016/j.ddmod.2014.02.004.
17.
Mirsattari SM, Sharpe MD, Young GB. Treatment of refractory status epilepticus with inhalational anesthetic agents isoflurane and desflurane. Arch Neurol 2004; 61: 1254-1259. DOI: 10.1001/archneur. 61.8.1254.
18.
Kikuchi C, Dosenovic S, Bienengraeber M. Anaesthetics as cardioprotectants: translatability and mechanism. Br J Pharmacol 2015; 172: 2051-2061. DOI: 10.1111/bph.12981.
19.
Li L, Zuo Z. Isoflurane postconditioning induces neuroprotection via Akt activation and attenuation of increased mitochondrial membrane permeability. Neuroscience 2011; 199: 44-50. DOI: 10.1016/j.neuroscience.2011.10.022.
20.
Jabaudon M, Boucher P, Imhoff E, Chabanne R, Faure JS, Roszyk L, et al. Sevoflurane for sedation in acute respiratory distress syndrome. a randomized controlled pilot study. Am J Respir Crit Care Med 2017; 195: 792-800. DOI: 10.1164/rccm.201604-0686OC.
21.
Englert JA, Macias AA, Amador-Munoz D, Pinilla Vera M, Isabelle C, Guan J, et al. Isoflurane ameliorates acute lung injury by preserving epithelial tight junction integrity. Anesthesiology 2015; 123: 377-388. DOI: 10.1097/ALN.0000000000000742.
22.
Oshima T, Karasawa F, Okazaki Y, Wada H, Satoh T. Effects of sevoflurane on cerebral blood flow and cerebral metabolic rate of oxygen in human beings: a comparison with isoflurane. Eur J Anaesthesiol 2003; 20: 543-547. DOI: 10.1017/s0265021503000863.
23.
Miranda AD, Donovan LA, Schuster LL, Gerber DR. Malignant hyperthermia. Am J Crit Care 1997; 6: 368-374; quiz 375-376.
24.
Kraus MB, Leuzinger K, Reynolds E, Gallo de Moraes A, Smith J, Sharpe EE, et al. Diabetes insipidus related to sedation in the intensive care unit: a review of the literature. J Crit Care 2023; 75: 154233. DOI: 10.1016/j.jcrc.2022.154233.
25.
Dupuis C, Robert A, Gerard L, Morelle J, Laterre PF, Hantson P. Nephrogenic diabetes insipidus following an off-label administration of sevoflurane for prolonged sedation in a COVID-19 patient and possible influence on aquaporin-2 renal expression. Case Rep Anesthesiol 2022; 2022: 3312306. DOI: 10.1155/2022/3312306.
26.
Sackey PV, Martling CR, Granath F, Radell PJ. Prolonged isoflurane sedation of intensive care unit patients with the Anesthetic Conserving Device. Crit Care Med 2004; 32: 2241-2246. DOI: 10.1097/01.ccm.0000145951.76082.77.
27.
Meiser A, Volk T, Wallenborn J, Guenther U, Becher T, Bracht H, et al. Inhaled isoflurane via the anaesthetic conserving device versus propofol for sedation of invasively ventilated patients in intensive care units in Germany and Slovenia: an open-label, phase 3, randomised controlled, non-inferiority trial. Lancet Respir Med 2021; 9: 1231-1240. DOI: 10.1016/S2213-2600(21)00323-4.
28.
Soukup J, Michel P, Christel A, Schittek GA, Wagner NM, Kellner P. Prolonged sedation with sevoflurane in comparison to intravenous sedation in critically ill patients – a randomized controlled trial. J Crit Care 2023; 74: 154251. DOI: 10.1016/j.jcrc.2022.154251.
29.
Jerath A, Beattie SW, Chandy T, Karski J, Djaiani G, Rao V, et al.; Perioperative Anesthesia Clinical Trials Group. Volatile-based short-term sedation in cardiac surgical patients: a prospective randomized controlled trial. Crit Care Med 2015; 43: 1062-1069. DOI: 10.1097/CCM.0000000000000938.
30.
Flinspach AN, Raimann FJ, Kaiser P, Pfaff M, Zacharowski K, Neef V, Adam EH. Volatile versus propofol sedation after cardiac valve surgery: a single-center prospective randomized controlled trial. Crit Care 2024; 28: 111. DOI: 10.1186/s13054-024-04899-y.
31.
Hellström J, Öwall A, Martling CR, Sackey PV. Inhaled isoflurane sedation during therapeutic hypothermia after cardiac arrest: a case series. Crit Care Med 2014; 42: e161-166. DOI: 10.1097/CCM. 0b013e3182a643d7.
32.
Jerath A, Ferguson ND, Cuthbertson B. Inhalational volatile-based sedation for COVID-19 pneumonia and ARDS. Intensive Care Med 2020; 46: 1563-1566. DOI: 10.1007/s00134-020-06154-8.
33.
Blondonnet R, Simand LA, Vidal P, Borao L, Bourguignon N, Morand D, et al. Design and rationale of the sevoflurane for sedation in acute respiratory distress syndrome (SESAR) randomized controlled trial. J Clin Med 2022; 11: 2796. DOI: 10.3390/jcm11102796.
34.
Beck-Schimmer B, Schadde E, Pietsch U, Filipovic M, Dübendorfer- Dalbert S, Fodor P, et al. Early sevoflurane sedation in severe COVID-19-related lung injury patients. A pilot randomized controlled trial. Ann Intensive Care 2024; 14: 41. DOI: 10.1186/s13613-024-01276-4.
35.
Rand A, Zahn PK, Schildhauer TA, Waydhas C, Hamsen U. Inhalative sedation with small tidal volumes under venovenous ECMO. J Artif Organs 2018; 21: 201-205. DOI: 10.1007/s10047-018-1030-9.
36.
Pickworth T, Jerath A, DeVine R, Kherani N, Wąsowicz M. The scavenging of volatile anesthetic agents in the cardiovascular intensive care unit environment: a technical report. Can J Anaesth 2013; 60: 38-43. DOI: 10.1007/s12630-012-9814-5.
37.
Wong K, Wasowicz M, Grewal D, Fowler T, Ng M, Ferguson ND, et al. Efficacy of a simple scavenging system for long-term critical care sedation using volatile agent-based anesthesia. Can J Anaesth 2016; 63: 630-632. DOI: 10.1007/s12630-015-0562-1.
38.
Jerath A, Panckhurst J, Parotto M, Lightfoot N, Wasowicz M, Ferguson ND, et al. Safety and efficacy of volatile anesthetic agents compared with standard intravenous midazolam/propofol sedation in ventilated critical care patients: a meta-analysis and systematic review of prospective trials. Anesth Analg 2017; 124: 1190-1199. DOI: 10.1213/ANE.0000000000001634.
39.
Cuninghame S, Jerath A, Gorsky K, Sivajohan A, Francoeur C, Withington D, et al. Effect of inhaled anaesthetics on cognitive and psychiatric outcomes in critically ill adults: a systematic review and meta-analysis. Br J Anaesth 2023; 131: 788. DOI: 10.1016/j.bja.2023.07.009.
40.
Jabaudon M, Quenot JP, Badie J, Audard J, Jaber S, Rieu B, et al. Inhaled sedation in acute respiratory distress syndrome: the SESAR randomized clinical trial. JAMA 2025; 333: 1608-1617. DOI: 10.1001/jama.2025.3169.
41.
Boncyk C, Devlin JW, Faisal H, Girard TD, Hsu SH, Jabaley CS, et al. INhaled Sedation versus Propofol in REspiratory failure in the Intensive Care Unit (INSPiRE-ICU1): protocol for a randomised, controlled trial. BMJ Open 2024; 14: e086946. DOI: 10.1136/bmjopen-2024-086946.
Share
RELATED ARTICLE
| eISSN: | 1731-2531 |
| ISSN: | 1642-5758 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
